Page 2 - Les meilleurs doctors traitant la maladie suivante : Chordome - TOP -53 des médecins

Dirige le département des lésions osseuses métastatiques du centre médical Ichilov, se concentrant particulièrement sur les cancers osseux complexes comme le chordome.

• Chirurgien orthopédiste spécialisé en orthopédie oncologique
• Professeur à la faculté de médecine de l'université de Tel Aviv
• Formé à l'Université hébraïque de Jérusalem
• Effectuer des stages cliniques aux États-Unis
• Médecin senior dans un centre d'orthopédie oncologique en Israël

Professeur associé à l'Université de médecine de Vienne et chef adjoint de sa division clinique d'oncologie – l'un des principaux centres de recherche sur le cancer en Autriche.

• Plus de deux décennies de spécialisation en oncologie médicale et en médecine interne
• Reconnu internationalement pour son expertise dans les thérapies ciblées des tumeurs solides
• Accent sur la médecine personnalisée contre le cancer et les traitements basés sur les biomarqueurs
• Contribution à la recherche translationnelle et conception de nouvelles stratégies de traitement de précision
• Consultant senior pour la thérapie systémique individualisée du cancer à la Wiener Privatklinik

Le professeur associé Dr Yusuf Acikgoz apporte son expertise internationale de l'Université d'État de l'Ohio à l'hôpital universitaire Lokman Hekim d'Ankara.

• Se spécialiser en oncologie médicale avec un accent sur les essais cliniques
• Participer à des études de phase III telles que CheckMate-649 et Fortitude-101
• Membre de l'American Society of Clinical Oncology (ASCO)
• Certifié en Bonnes Pratiques Cliniques et en Protection des Sujets Humains

Le professeur Keil se spécialise en radiologie interventionnelle, réalisant des interventions médicales complexes à l'aide de techniques d'imagerie avancées au centre médical de Solingen.

• Diplômé avec mention de l'Université Julius-Maximilian de Würzburg
• Expert en IRM, scanner et procédures guidées par échographie
• Ancien médecin principal au centre hospitalier universitaire d'Aix-la-Chapelle
• Médecin-chef à l'hôpital académique de Solingen depuis 2022

Dr. Mariam Mohammed Hussein Abu Zeid is a clinical oncologist. She treats solid tumors and hematologic cancers. She earned her MBBCh from Ain Shams University in 2007 (Excellent). She completed a Master’s in Clinical Oncology and Nuclear Medicine in 2011 (Very Good). She received a Ph.D. in 2018 and an ESMO Certificate in 2015.

She leads and monitors clinical trials. Her work includes data collection and analysis. She administers chemotherapy and manages treatment toxicities. She also plans care with multidisciplinary teams. Her experience includes Ain Shams University Hospitals (2009–2012), the International Medical Center (2012–2014), and Wadi El Nile Hospital (2015–2019). Her roles covered diagnosis and staging, supportive care, quality improvement, and screening. She educates patients and families about the diagnosis, treatment options, and palliative care.

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Le Dr Nail Paksoy apporte une expertise spécialisée en oncologie, se concentrant sur les cas complexes à l'hôpital Medipol Bahçelievler.

• Certifié en oncologie médicale par l'ESMO
• Publier de nombreuses études sur les cancers rares et les traitements innovants
• Participer activement à des essais cliniques internationaux en oncologie
• Professeur associé à l'Université Medipol d'Istanbul

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Plus de 30 ans d'expérience spécialisée en virothérapie – l'un des domaines les plus récents de l'immunologie – à la Clinique Pallas.

• Chef du Centre d'immunologie clinique de l'Hôpital universitaire clinique Pauls Stradins
• Diplômé de l'Institut médical de Riga avec un internat en médecine interne
• Expert en traitements immunologiques pouvant être adaptés à des pathologies spécifiques

Le Dr Alemdar est spécialisé en oncologie médicale au complexe hospitalier Medical Park Antalya, avec une formation approfondie en médecine interne et en oncologie.

• Certifié en oncologie médicale depuis 2018
• Plus de 15 ans d'expérience médicale dans divers hôpitaux
• Formation spécialisée à la faculté de médecine de l'université Akdeniz
• Travailler avec une approche multidisciplinaire pour des soins complets contre le cancer

Dr. Emad Shash, M.B.B.Ch, MSc, M.D., is a medical oncologist. He is the Medical Director of the Breast Comprehensive Cancer Hospital at NCI. He leads the Medical Oncology Department and is the Breast Program Director at Shifaa Al Orman Cancer Hospital in Luxor. His clinical focus includes breast, gynecologic, genitourinary, thoracic, gastrointestinal, and rare cancers. He specializes in systemic therapy, including chemotherapy, targeted therapy, and immunotherapy.

He served as coordinating research physician and medical lead at the EORTC from 2011 to 2015. Since 2008, he has contributed to more than 70 international oncology trials as a coordinator, sub-investigator, principal investigator, and sponsor medical monitor. Credentials include M.B.B.Ch (2004), MSc (2010), MD (2015), and the EORTC Certificate of Excellence (2015). He also holds a Diploma in Hospital Quality Management & Patient Safety (JCI/57357, 2017). He is a Fellow of the EIO. He is a member of ESMO (panel voting), ESGO, and ASCO (IAC), and serves on the ECRIN board.

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

Dr. Maha Yahia is a medical oncologist and hemato-oncologist. She provides assessment, diagnosis, and treatment planning. Her treatments include chemotherapy, targeted therapy, and immunotherapy. She cares for patients with breast, genitourinary, gynecologic, thoracic, gastrointestinal, and rare cancers.

Education: M.B.B.Ch, Kasr El-Aini, Cairo University (1997–2003). Master in Hemato-oncology, National Cancer Institute, Cairo University (2008). Doctoral Degree in Hemato-oncology, National Cancer Institute, Cairo University (2015).

Experience: Resident in Medical Oncology, Maadi AFMC (2005–2010). Visitor Resident, NCI Cairo (2008–2009). Consultant Assistant, Prof. Hussein Khaled Clinic (2010–2017). Specialist, International Medical Center (2011–2012), Wadi El Nile Hospital (2013–2014), and Maadi AFMC (2011–2018). Head, Clinical Research Support Team, Maadi AFMC (2016–2018). Major (2014–2016) and Lt. Colonel Doctor (2016–2018), Egyptian Armed Forces. Lecturer of Clinical Research, AFCM (2019–2021).

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Spécialisé en radio-oncologie avec une formation de l'Université de Marmara, réputée pour son programme médical rigoureux.

• Formé au département de radio-oncologie de l'Université de Marmara
• Études de médecine de premier cycle terminées à l'Université de Marmara
• La formation comprend une expérience internationale en Azerbaïdjan

Le Dr Topcu apporte son expertise internationale du MD Anderson et du Sunnybrook Odette Cancer Center à l'hôpital universitaire Biruni.

• Se spécialiser dans les cancers rares, notamment le chordome et les sarcomes
• Membre de l'ESMO et de l'ASCO – standards mondiaux en oncologie
• Formation dans des institutions de premier plan aux États-Unis, au Canada et en Turquie
• Travailler sur de multiples types de cancers avec des cas complexes